Crossmark

Epidemiology of rehabilitation practices for inpatients with nephrotic syndrome: a retrospective cohort study using an administrative database

Crossref DOI link: https://doi.org/10.1007/s10157-026-02832-x

Published Online: 2026-02-24

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shinkawa, Kanna

Yoshida, Satomi

Nakao, Yoko M.

Hayashi, Ayano

Sakoda, Kazunori

Yanagita, Motoko

Kawakami, Koji https://orcid.org/0000-0002-7477-4071
License Information

Text and Data Mining valid from 2026-02-24

Version of Record valid from 2026-02-24
More Information

Article History

Received: 17 June 2025

Accepted: 13 February 2026

First Online: 24 February 2026

Declarations

:

: SY has received consulting fees from TOYOTA Konpon Research Institute Inc. YMN has been employed by the Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health, Kyoto University with support from Eisai Co., Ltd. and Kyowa Kirin Co., Ltd., and has received a research grant from Bayer outside of this work. KK has received research funds from AstraZeneca K.K., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., OMRON Corporation, and Toppan Inc.; consulting fees from Advanced Medical Care Inc., JMDC Inc., LEBER Inc., Ubicom Holdings, Inc., Santen Pharmaceutical Co., Ltd., and Shin Nippon Biomedical Laboratories Ltd.; executive compensation from Cancer Intelligence Care Systems, Inc. and Mytreya Inc.; honoraria from Kyoto University Original Co., Ltd., Pharma Business Academy Ltd., Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., and SANSHO Co., Ltd; and held stock in Real World Data Co., Ltd. MY has received research funding from the Japan Agency for Medical Research and Development (AMED), including the Platform Program for Promotion of Genome Medicine, AMED–CREST, the Translational Research Program, the Moonshot Research and Development Program, and the Project for Elucidation of the Role of Tertiary Lymphoid Tissue; from the Japan Society for the Promotion of Science (JSPS) through Grants-in-Aid for Scientific Research (B, C, and Challenging Exploratory Research); grants from Boehringer Ingelheim GmbH; and honoraria for lectures or presentations from Astellas Pharma Inc., AstraZeneca K.K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Chugai Pharmaceutical Co., Ltd.

: The study was approved by the Ethics Committee of the Kyoto University Graduate School and Faculty of Medicine (approval number: R1226).

: Obtaining informed consent from individual patients was waived, because this study was a secondary analysis of an anonymous patient database.

Document is current

Any future updates will be listed below